New developments in neonatal intensive care units (NICUs) regarding ventilation techniques, antenatal steroid treatment, and surfactant therapy have decreased lung disease-related morbidity and mortality in newborns.\(^1\)\(^-\)\(^3\) Despite the use of surfactant treatments with high-frequency oscillation or volume guarantee ventilation methods, bronchopulmonary dysplasia (BPD) is still the most important cause of pulmonary morbidity in preterm infants.\(^2\)\(^,\)\(^4\) Invasive mechanical ventilation is an important environmental risk factor for BPD due to volutrauma, barotrauma, and atelectotrauma.\(^4\) In recent years, various non-invasive respiratory support (NRS) techniques have been used in neonates.\(^5\) The aim of this study was to compare the effects of heated humidified high-flow nasal cannula (HHHFNC), continuous positive airway pressure (CPAP), nasal intermittent positive-pressure ventilation (NIPPV), and nasal high-frequency oscillation ventilation (NHFOV) were compared in preterm infants with respiratory distress.\(^5\)

**ABSTRACT**

**Background.** The use of non-invasive ventilation methods in neonatal intensive care units has been increasing in recent years. Non-invasive ventilation techniques are lung preserving methods and they reduce the risk of volutrauma, barotrauma, and atelectotrauma.

**Methods.** The effect of heated humidified high-flow nasal cannula (HHHFNC), continuous positive airway pressure (CPAP), nasal intermittent positive-pressure ventilation (NIPPV), and nasal high-frequency oscillation ventilation (NHFOV) were compared in preterm infants with respiratory distress.

**Results.** Between December 2015 and February 2017, a total of 76 preterm infants (gestational age <32 weeks) with respiratory distress were enrolled in this study. Of the patients, 20 received CPAP (NCPAP), 19 received NIPPV, 17 received NHFOV, and 17 received HHHFNC for respiratory support. The primary outcome was intubation requirement during non-invasive respiratory support. The secondary outcome included duration of non-invasive ventilation, air leak syndrome, abdominal distension, intraventricular hemorrhage, necrotizing enterocolitis (NEC), nasal injury, increased secretions, agitation, and mortality rate. The intubation ratio was higher in the NCPAP (40%) and NHFOV (29.4%) groups when compared with the NIPPV (10.5%) and HHHFNC (11.8%) groups. More nasal injury had developed in the NIPPV (78.9%) and NHFOV (82.4%) groups when compared with the NCPAP (40%) and HHHFNC (35%) groups. Moreover, the viscous secretion that blocked the cannulas was higher in NIPPV (78.9%) and NHFOV (76.5%) groups than NCPAP (25%) and HHHFNC (40%) groups. There were no significant differences in the duration of non-invasive ventilation methods, abdominal distension, NEC, air leak syndrome or mortality in the 4 groups.

**Conclusions.** The NIPPV and HHHFNC methods can be useful as a primary mode of respiratory support for respiratory distress. However, doctors need to be careful with regard to the complications that may develop.

**Key words:** non-invasive ventilation, preterm, respiratory support, different techniques, efficiency.
positive-pressure ventilation (NIPPV), and nasal high-frequency oscillation ventilation (NHFOV) in preterm infants with respiratory distress.

Material and Methods

This study was performed at Hacettepe University NICU between December 2015 and February 2017. Ethical approval was obtained from the institutional Hacettepe University, Clinical Research Ethics Committee (IRB number: 16969557-1327; GO 17/38-11) and participation involved informed consent. A total of 76 preterm infants (gestational age <32 weeks) with respiratory distress were enrolled in this study. All of the infants were supported with NCPAP (positive-end expiratory pressure (PEEP): 5 cm H\textsubscript{2}O\textsuperscript{2}) in the delivery room and admitted to the NICU with CPAP. The newborns were randomly allocated into a nasal treatment mode of either HHHFNC, NCPAP, NIPPV, or NHFOV. During the study, 20 patients received HHHFNC, while 20 patients received NCPAP, 19 patients received NIPPV, and 17 patients received NHFOV for respiratory support. Newborns who required mechanical ventilation were excluded from the study. Moreover, newborns with congenital malformations or inherited metabolic diseases were also excluded.

All of the infants were loaded with caffeine citrate on their first day of life (10 mg/kg) and this continued each day. Data of the maternal characteristics (age, gestational age, mode of delivery, prenatal corticosteroid administrations, prematurity membrane rupture (PPROM), chorioamnionitis), and neonatal characteristics (birth weight, gender, 5-min Apgar score, etc.) of the patients were collected.

NCPAP

The NCPAP support was delivered via the bubble CPAP system (Fisher & Paykel Healthcare, Auckland, New Zealand), which generates continuous positive airway pressure, applied through short binasal prongs used as an interface (Optiflow Junior 2 nasal cannula). The respiratory pressure of the NCPAP was 5–6 cm H\textsubscript{2}O\textsuperscript{2).

NIPPV

The NIPPV support was delivered via a conventional ventilator device (Drager Babylog 8000; Lübeck, Germany), which generates intermittent positive pressure ventilation, applied through short binasal prongs used as an interface (Optiflow Junior 2 nasal cannula). The initial ventilator parameters were PEEP: 5–6 cm H\textsubscript{2}O\textsuperscript{2}; peak inspiratory pressure: 15–20 cm H\textsubscript{2}O; inspiratory time 0.4–0.5 s; respiratory rate 25–30 breaths/min.

NHFOV

The NHFOV support was delivered via a high-frequency oscillation ventilator (Drager Babylog 8000), applied through short binasal prongs used as an interface (Optiflow Junior 2 nasal cannula). The initial ventilator parameters were mean arterial pressure: 6 cm H\textsubscript{2}O; Delta P: 100% and rate: 10 Hz.

HHHFNC

The HHHFNC support was delivered via a precision flow device (Precision Flow, Vapotherm, Inc, Exeter, NH, USA), applied through the small bore cannula in the Vapotherm as an interface. The initial nasal flow parameters were: flow: 5 L/min, heat: 37 °C.

The fraction of inspired oxygen (FiO\textsubscript{2}) was set in all of the NRS techniques with the target pulse oximeter rate of 90%–95%.

Non-invasive ventilation failure criteria included acidosis and hypercarbia (pH <7.20 and pCO\textsubscript{2} >65 mmHg), apnea (≥2 episodes/h), and necrotizing enterocolitis (NEC) in the gastrointestinal tract. The criteria of surfactant administration included a FiO\textsubscript{2} requirement higher than 0.4. The first dose of surfactant was 200 mg/kg (Curosurf, Chiesi, Parma, Italy) and an additional dose of 100 mg/kg was given at least 6 h after the previous administration.
total of 54 patients had received minimally invasive surfactant therapy.

The primary outcome was the requirement of intubation during NRS. The secondary outcomes comprised the duration of non-invasive ventilation (days), air leak syndrome, abdominal distension, intraventricular hemorrhage (IVH), NEC, nasal injury, increased secretions, agitation, and mortality rate. N-PASS (Neonatal Pain Agitation and Sedation Scale) was used for diagnosis of pain and agitation and to determine the necessity of sedation.

**Statistical analysis**

For the calculation of the sample size, the rate of intubation requirement was used as the main primary outcome. A confidence level of $\alpha = 0.05$ We used; the power level desired was 0.80, and consequently, 15 patients were needed for each group. Parameters of the 4 groups were compared using 1-way ANOVA for the continuous variables and the chi square test was performed for the categorical variables. Statistical significance was accepted as $P < 0.05$. Statistical analysis was performed using IBM SPSS Statistics for Windows (SPSS Inc., Chicago, IL, USA).

**Results**

The birth weight, gestational week (GW), maternal age, Apgar score, type of delivery, PPROM, and infection were evaluated as maternal and gestational properties. The median birth weight was 1190 g (600–2010) and the median GW was 28 weeks (26–32) in the HHHFNC group, while the median birth weight was 1240 g (580–2010) and the median GW was 28 (26–32) weeks in the NCPAP group. Moreover, the median birth weight was 1130 g (530–2550) and the median GW was 28 weeks (26–32) in the NIPPV group, while median birth weight was 1250 g (800–2240) and the median GW was 29 (27–32) weeks in the NHFOV group. There were no significant differences in the maternal and gestational features ($P > 0.05$) (Table I).

Of the patients, 54 needed surfactant therapy, but there were no significant differences in the surfactant necessity between the 4 groups ($P > 0.05$) (Table II).

The mean duration of NRS was 6.2 days in the HHHFNC group, 5 days in the NCPAP group, 3.4 days in the NIPPV group, and 4.2 days in the NHFOV group ($P > 0.05$). Additionally, there were no significant differences in the abdominal distension, NEC, air leak syndrome,

**Table I.** Maternal and gestational features of NRS groups.

|                        | HHHFNC (n=20) | NCPAP (n=20) | NIPPV (n=19) | NHFOV (n=17) | p value |
|------------------------|---------------|--------------|--------------|--------------|---------|
| Birth weight (g)       | 1190          | 1240         | 1130         | 1250         | 0.69    |
| Median (min-max)       | (600-2010)    | (580-2010)   | (530-2550)   | (800-2240)   |         |
| GW (week)              | 28 weeks      | 28 weeks     | 28 weeks     | 29 weeks     | 0.58    |
| Median (min-max)       | (26-32)       | (26-32)      | (26-32)      | (27-32)      |         |
| Maternal age (year)    | 30.4 ± 5.8    | 29.9 ± 4.7   | 32.2 ± 4.4   | 30.2 ± 5.3   | 0.51    |
| mean ± SD              |               |              |              |              |         |
| Apgar (5th min)        | 9 (3-10)      | 9 (3-10)     | 8 (3-10)     | 9 (3-10)     | 0.48    |
| C/S, n (%)             | 19 (95)       | 20 (100)     | 19 (100)     | 16 (94)      | 0.59    |
| PPROM, n(%)            | 1 (5)         | 3 (15)       | 1 (5)        | 2 (12)       | 0.65    |
| Chorioamnionitis, n(%) | 1 (5)         | 1 (5)        | 0 (0)        | 0 (0)        | 1.0     |
| Antenatal steroid, n(%)| 6 (30)        | 5 (25)       | 7 (37)       | 11 (65)      | 0.07    |

HHHFNC: Heated humidified high-flow nasal canula, NCPAP: Nasal continuous positive airway pressure, NIPPV: Nasal intermittent positive pressure ventilation, NHFOV: Nasal high-frequency oscillation ventilation, SD: Standart deviation, GW: Gestation week.

Apgar: Apgar score. C/S: Cesarian section. PPROM: Preterm premature rupture of membranes.
and mortality in the 4 groups (P > 0.05). Patients who had a N-PASS score of more than 3 required sedation. There were no significant differences between the groups (P > 0.05) (Table III).

The intubation ratio was higher in the NCPAP (40%) and NHFOV (29.4%) groups when compared with the NIPPV (10.5%) and HHHFNC (11.8%) groups (P < 0.05). Viscous secretion that blocked cannulas and required recurrent aspiration was present in the NIPPV (78.9%) and NHFOV (76.5%) groups when compared with the NCPAP (25%) and HHHFNC (40%) groups (P < 0.05). More nasal injury (nasal bleeding and ulceration) developed in the NIPPV (78.9%) and NHFOV (82.4%) groups when compared with the NCPAP (40%) and HHHFNC (35%) groups (P < 0.05). Moreover, more IVH was observed in the NIPPV (21.1%) and HHHFNC (10%) groups than in any of the other groups (P < 0.05) (Table IV).

We also separately evaluated small preterm infants whose gestational ages were below 28 weeks in the study group (Table V). The mean birth weight was not different between groups (P > 0.05). The intubation ratio was higher in the NCPAP (60%) and NHFOV (37%) groups when compared with the NIPPV (9%) and HHHFNC (15%) groups (P < 0.05). Viscous secretion was present in the NIPPV (90%) and NHFOV (80%) groups when compared with the NCPAP (30%) and HHHFNC (61%) groups (P < 0.05). There is no significant difference between the groups in terms of other morbidities (P > 0.05).

Discussion

In recent years, NRS methods have become the first respiratory support strategies in NICUs to prevent the development of BPD. Hence, there are many studies comparing NRS methods and their results in the literature. In this context, the use of different NRS methods has been proposed in different studies.

In this study, it was found that the HHHFNC and NIPPV groups had lower failure rates than the NCPAP and NHFOV groups. The intubation requirement was higher in the NCPAP and NHFOV groups. In a meta-analysis including 10 trials, NIPPV was stated as more efficient than NCPAP concerning the ratio of respiratory failure and intubation requirement. Furthermore, in previous

Table II. Surfactant necessity of infants in NRS groups

|                  | HHHFNC | NCPAP | NIPPV | NHFOV | p value |
|------------------|--------|-------|-------|-------|---------|
| Single dose surfactant | 7      | 8     | 5     | 5     | 0.84    |
| Two doses surfactant  | 2      | 3     | 2     | 4     | 0.67    |
| Three doses surfactant | 5      | 4     | 7     | 2     | 0.35    |

HHHFNC: Heated humidified high-flow nasal canula, NCPAP: Nasal continuous positive airway pressure, NIPPV: Nasal intermittent positive pressure ventilation, NHFOV: Nasal high-frequency oscillation ventilation.

Table III. Duration of ventilation and NRS related complications in NRS groups

|                  | HHHFNC (n=20) | NCPAP (n=20) | NIPPV (n=19) | NHFOV (n=17) | p value |
|------------------|---------------|--------------|--------------|--------------|---------|
| NRS duration (day) | 6.2 (2-25)    | 5 (2-15)     | 3.4 (2-12)   | 4.2 (2-8)    | 0.11    |
| Air leak n(%)    | 0 (0)         | 0 (0)        | 1 (5.3)      | 1 (5.9)      | 0.22    |
| Abdominal distension n(%) | 8 (40.0) | 7 (35.0) | 5 (26.3) | 8 (47.0) | 0.62    |
| NEC, n(%)        | 2 (10)        | 0 (0)        | 1 (5.3)      | 0 (0)        | 0.50    |
| N-PASS score n(score>3) | 5/20   | 5/20         | 5/19         | 4/17         | 0.54    |
| Mortality, n(%)  | 0 (0)         | 1 (5.0)      | 0 (0)        | 0 (0)        | 1.0     |

HHHFNC: Heated humidified high-flow nasal canula, NCPAP: Nasal continuous positive airway pressure, NIPPV: Nasal intermittent positive pressure ventilation, NHFOV: Nasal high-frequency oscillation ventilation, NRS: Noninvasive respiratory support, NEC: Necrotizing enterocolitis, N-PASS: Neonatal pain agitation and sedation scale.
studies with preterm infants, intubation rates were lower with NIPPV than with NCPAP.14-16 Li et al.17 compared NCPAP and NIPPV as the primary mode of respiratory support. They stated that there was a significant decrease in the intubation need and invasive ventilation in the NIPPV group, as in the current study. But we already know that synchronisation in NIPPV has much better results concerning the requirement for intubation and lung damage that will lead to the development of BPD.18 One of the limitations in our study was that we could

---

**Table IV.** Non-invasive ventilation failure and procedure comorbid complications.

|                          | HHHFNC (n=20) | NCPAP (n=20) | NIPPV (n=19) | NHFOV (n=17) | p value |
|--------------------------|---------------|--------------|--------------|--------------|---------|
| Number of intubated infants after NIV n(%) | 2(10) | 8(40) | 2(10.5) | 5(29.4) | 0.04 |
| Viscous secretion n(%)   | 8(40) | 5(25) | 15(78.9) | 13(76.5) | 0.001 |
| IVH n(%) (Grade 1)       | 2(10) | 0(0) | 4(21.1) | 0(0) | 0.04 |
| Sepsis n(%)              | 7(35) | 8(40) | 9(47.3) | 6(35.2) | 0.85 |
| PDA n(%)                 | 3(15) | 5(25) | 5(26.3) | 3(17.6) | 0.81 |
| Nasal injury n(%)        | 7(35) | 8(40) | 15(78.9) | 14(82.4) | 0.002 |
| BPD n(%)                 | 6(30) | 3(15) | 10(52.6) | 6(35.2) | 1.0 |

HHHFNC: Heated humidified high-flow nasal canula, NCPAP: Nasal continuous positive airway pressure, NIPPV: Nasal intermittent positive pressure ventilation, NHFOV: Nasal high-frequency oscillation ventilation, IVH: Intraventricular hemorrhage, PDA: Patent ductus arteriosus, BPD: Bronchopulmonary dysplasia.

---

**Table V.** Comparison of patient group findings under 28 weeks of gestation.

|                          | HHHFNC (n=13) | NCPAP (n=10) | NIPPV (n=11) | NHFOV (n=8) | p value |
|--------------------------|---------------|--------------|--------------|-------------|---------|
| NRS duration (day)(mean) | 7.9 | 4.1 | 6.1 | 4.5 | 0.15 |
| (min-max)                | (5-25) | (3-15) | (2-12) | (3-8) |         |
| GW (week)                | 27 weeks | 27 weeks | 27 weeks | 27 weeks | 0.79 |
| Median(min-max)          | (26-27) | (26-27) | (26-27) | (27-27) |         |
| Birth weight (g)         | 1066.5±328 | 1180 ±396 | 1032.7 ±370 | 1145 ±265 | 0.59 |
| mean ± SD (600-1660)     | (580-1770) | (530-1760) | (800-1510) |         |         |
| Apgar (5th min)          | 8 (3-10) | 7 (3-10) | 7 (3-10) | 8 (3-10) | 0.95 |
| C/S, n (%)               | 12(92) | 10(100) | 11(100) | 8(100) | 0.51 |
| PPROM, n(%)              | 1(7) | 3(30) | 1(9) | 1(12) | 0.43 |
| Antenatal steroid, n(%)  | 5(38) | 4(40) | 5(45) | 5(63) | 0.72 |
| Abdominal distension, n(%) | 6(46) | 5(50) | 3(27) | 4(50) | 0.67 |
| N-PASS score n(score>3)  | 4 (30) | 4(40) | 3(27) | 3(37) | 0.23 |
| Number of intubated infants after NIV n(%) | 2(15) | 6(60) | 1(9) | 3(37) | 0.02 |
| Viscous secretion, n(%)  | 8(61) | 3(30) | 10(90) | 7(87) | 0.01 |
| Sepsis, n(%)             | 7(53) | 6(60) | 7(63) | 4(50) | 0.93 |
| PDA, n(%)                | 3(23) | 5(50) | 5(45) | 3(37) | 0.55 |
| Nasal injury, n(%)       | 7(53) | 5(50) | 10(90) | 7(87) | 0.08 |
| BPD, n(%)                | 5(38) | 3(30) | 5(45) | 3(37) | 0.69 |

HHHFNC: Heated humidified high-flow nasal canula, NCPAP: Nasal continuous positive airway pressure, NIPPV: Nasal intermittent positive pressure ventilation, NHFOV: Nasal high-frequency oscillation ventilation, IVH: Intraventricular hemorrhage, PDA: Patent ductus arteriosus, BPD: Bronchopulmonary dysplasia.
not do synchronized NIPPV. However, there are studies in the literature showing that BPD, mortality, NEC and IVH rates do not change when synchronization is achieved.\(^{19}\) Also no significant difference was found in the BPD and mortality in patients below 28 weeks GA.

According to previous studies, NHFOV does not require synchronization and caused less barotrauma.\(^{20-22}\) However, similar to the current findings herein, Czernik et al.\(^{23}\) determined a high risk of respiratory failure in extremely preterm babies. Moreover, a survey of 5 European countries described the side effects of NHFOV as agitation, viscous secretions, and upper airway obstruction associated efficiency problems. As a result of the higher mean pressures with NHFOV, abdominal distention becomes another side effect of this technique.\(^{24}\) Viscous secretions and the need for very frequent aspiration was observed in the NHFOV group in the current study. It was also speculated that the use of a relatively low frequency at high amplitude with NHFOV causes excessive viscous secretion formation in the upper airway.\(^{25}\) On the other hand, in babies below 28 weeks GA, nasal secretion rates were found to be high in all NRS groups except NCPAP group in the current study. Although ventilator-associated pneumonia and congenital pneumonia may cause increased secretion, pneumonia was not detected in our study cases. Pulmonary findings of our RDS cases regressed after surfactant treatment.

Additionally, the abdominal distension ratio was relatively higher in the NHFOV group than in the other groups herein, but it was not statistically significant.

In recent years, HHHFNC has been used in NICUs as a NRS.\(^{26}\) Observed in the current study was a lower failure rate in the HHHFNC group when compared with the NCPAP group. Roberts et al.\(^{27}\) compared NCPAP and HHHFNC as the primary mode of respiratory support and found a higher failure rate in the HHHFNC group. However, in their study, they used this method for early respiratory support without the use of a surfactant. Surfactant treatment was also given to the infants in the current study. Another randomized clinical trial found an increase rate of intubation in the HHHFNC group when compared with the NCPAP group.\(^{28}\)

However, it was reported that flow levels higher than 4 L/min could solve this problem. In the present study, the initial nasal flow rate was 5 L/min. There were no differences observed in the efficacy and safety between the HHHFNC and NCPAP groups in a study involving 432 preterm babies.\(^{29}\) Surfactant administration and higher flow rates might explain the success of HHHFNC in the current study. However, efficiency of HHHFNC is still controversial when compared with nasal NCPAP. HHHFNC generates pressure in the nasopharyngeal area, and there is not enough information about how much pressure is reflected into the respiratory tract. High flow rates lead to increase pharyngeal pressure.\(^{30,31}\) Hence, the amount of pressure formed in the nasopharyngeal space is not exactly known.\(^{32,33}\) The same failure rate was also found in the HHHFNC group when compared with the NIPPV group. When we evaluate our preterm patients below 28 weeks GA, the failure rate was high in the NCPAP and HFOV groups again.

On the other hand, the NRS methods, in terms of comorbid complications, were also evaluated herein. No significant differences in the sepsis, air leak, hemodynamically significant patent ductus arteriosus, NEC, BPD, or mortality were found. Similar results were found in preterm babies below 28 weeks GA. In the NIPPV group, 4 IVHs were observed, while 2 IVH were observed in the HHHFNC group. However, the IVHs in these patients were grade 1 and there were no neurological symptoms. Another complication investigated was the nasal injury between the groups. Nasal injury was followed-up as granulation tissue, ulceration, necrosis, and deformation of the nasal septum and edge of the nostril. Nasal injuries were higher in the NHFOV and NIPPV groups than in the NCPAP group. This may have occurred due
to viscous secretions and mucosal dryness. Moreover, the least nasal injury was observed in the HHHFNC group, special nasal cannula of HHHFNC might explain this situation. This nasal cannula allows air to leak from the nostril and this reduces nasal injury. Although there was no statistical difference in our study, prolonged NRS duration is a risk factor for nasal injury. The N-PASS score was used to assess the comfort level of the patients, but no differences were found between the NRS groups.

In conclusion, this data suggested that the NIPPV and HHHFNC methods have beneficial effects on preterm infants in NICUs. These methods can be useful but they require more experience to use as a primary mode of respiratory support for RDS. NHFOV is thought to cause less barotrauma and damage to the lungs. However, doctors need to be careful with regards to its complications. Therefore, there is a need for further multicenter randomized controlled trials in a wider population.

REFERENCES

1. Lau HCQ, Tung JSZ, Wong TTC, Tan PL, Tagore S. Timing of antenatal steroids exposure and its effects on neonates. Arch Gynecol Obstet 2017; 296: 1091-1096.
2. Warren JB, Anderson JM. Newborn respiratory disorders. Pediatr Rev 2010; 31: 487-495.
3. Shim GH. Update of minimally invasive surfactant therapy. Korean J Pediatr 2017; 60: 273-281.
4. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723-1729.
5. Schmölzer GM, Kumar M, Pichler G, Aziz K, O’Reilly M, Cheung PY. Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis. BMJ 2013; 347: f5980.
6. Wright CJ, Kirpalani H. When should we start continuous positive airway pressure in the delivery room and how high should we go? Acta Paediatr 2016; 105: 868-870.
7. Trembath A, Laughon MM. Predictors of bronchopulmonary dysplasia. Clin Perinatol 2012; 39: 585-601.
8. Bhandari V. The potential of non-invasive ventilation to decrease BPD. Semin Perinatol 2013; 37: 108-114.
9. Wilkinson D, Andersen C, O’Donnell CP, De Paoli AG, Manley BJ. High flow nasal cannula for respiratory support in preterm infants. Cochrane Database Syst Rev 2016; 2: CD006405.
10. Shin J, Park K, Lee EH, Choi BM. Humidified high flow nasal cannula versus nasal continuous positive airway pressure as an initial respiratory support in preterm infants with respiratory distress: a randomized, controlled non-inferiority trial. J Korean Med Sci 2017; 32: 650-655.
11. Owen LS, Manley BJ. Nasal intermittent positive pressure ventilation in preterm infants: equipment, evidence, and synchronization. Semin Fetal Neonatal Med 2016; 21: 146-153.
12. Mukerji A, Finelli M, Belik J. Nasal high-frequency oscillation for lung carbon dioxide clearance in the newborn. Neonatology 2013; 103: 161-165.
13. Lemyre B, Laughon M, Bose C, Davis PG. Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants. Cochrane Database Syst Rev 2016; 12: CD005384.
14. Shi Y, Tang S, Zhao J, Shen J. A prospective, randomized, controlled study of NIPPV versus nCPAP in preterm and term infants with respiratory distress syndrome. Pediatr Pulmonol 2014; 49: 673-678.
15. Kugelman A, Feferkorn I, Riskin A, Chistyakov I, Kaufman B, Bader D. Nasal intermittent mandatory ventilation versus nasal continuous positive airway pressure for respiratory distress syndrome: a randomized, controlled, prospective study. J Pediatr 2007; 150: 521-526.
16. Silveira CST, Leonardi KM, Melo APCF, Zaia JE, Brunherotti MA. Response of preterm infants to 2 noninvasive ventilatory support systems: nasal CPAP and nasal intermittent positive-pressure ventilation. Respir Care 2015; 60: 1772-1776.
17. Li W, Long C, Zhangxue H, et al. Nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure for preterm infants with respiratory distress syndrome: a meta-analysis and up-date. Pediatr Pulmonol 2015; 50: 402-409.
18. Waitz M, Mense L, Kirpalani H, Lemyre B. Nasal intermittent positive pressure ventilation for preterm neonates: synchronized or not? Clin Perinatol 2016; 43: 799-816.
19. Dumpa V, Katz K, Northrup V, Bhandari V. SNIPPV vs NIPPV: does synchronization matter? J Perinatol 2012; 32: 438-442.
20. Hoehn T, Krause MF. Effective elimination of carbon dioxide by nasopharyngeal high-frequency ventilation. Respir Med 2000; 94: 1132-1134.
21. Aktas S, Unal S, Aksu M, et al. Nasal HFOV with binasal cannula appears effective and feasible in ELBW newborns. J Trop Pediatr 2016; 62: 165-168.

22. Colaizy TT, Younis UMM, Bell EF, Klein JM. Nasal high-frequency ventilation for premature infants. Acta Paediatr 2008; 97: 1518-1522.

23. Czernik C, Schmalisch G, Bührer C, Proquitte H. Weaning of neonates from mechanical ventilation by use of nasopharyngeal high-frequency oscillatory ventilation: a preliminary study. J Matern Fetal Neonatal Med 2012; 25: 374-378.

24. Fischer HS, Bohlin K, Bührer C, et al. Nasal high-frequency oscillation ventilation in neonates: a survey in five European countries. Eur J Pediatr 2015; 174: 465-471.

25. Ullrich TL, Czernik C, Buhrer C, Schmalisch G, Fischer HS. Nasal high-frequency oscillatory ventilation impairs heated humidification: a neonatal bench study. Pediatr Pulmonol 2017; 52: 1455-1460.

26. Permall DL, Pasha AB, Chen XQ. Current insights in non-invasive ventilation for the treatment of neonatal respiratory disease. Ital J Pediatr 2019; 45: 105.

27. Roberts CT, Owen LS, Manley BJ, et al; HIPSTER Trial Investigators Nasal high-flow therapy for primary respiratory support in preterm infants. N Engl J Med 2016; 375: 1142-1151.

28. Kadivar M, Mosayebi Z, Razi N, Nariman S, Sangsari R. High flow nasal Cannulae versus nasal continuous positive airway pressure in neonates with respiratory distress syndrome managed with INSURE method: a randomized clinical trial. Iran J Med Sci 2016; 41: 494-500.

29. Yoder BA, Stoddard RA, Li M, King J, Dinrberger DR, Abbasi S. Heated, humidified high-flow nasal cannula versus nasal CPAP for respiratory support in neonates. Pediatrics 2013; 131: e1482-e1490.

30. Collins CL, Holberton JR, Barfield C, Davis PG. A randomized controlled trial to compare heated humidified high-flow nasal cannulae with nasal continuous positive airway pressure postextubation in premature infants. J Pediatr 2013; 162: 949-954.

31. Arora B, Mahajan P, Zidan MA, Sethuraman U. Nasopharyngeal airway pressures in bronchiolitis patients treated with high-flow nasal cannula oxygen therapy. Pediatr Emerg Care 2012; 28: 1179-1184.

32. Wilkinson DJ, Andersen CC, Smith K, Holberton J. Pharyngeal pressure with high-flow nasal cannulae in premature infants. J Perinatol 2008; 28: 42-47.

33. Sreenan C, Lemke RP, Hudson-Mason A, Osiovich H. High-flow nasal cannulae in the management of apnea of prematurity: a comparison with conventional nasal continuous positive airway pressure. Pediatrics 2001; 107: 1081-1083.

34. Jatana KR, Oplatek A, Stein M, Phillips G, Kang DR, Elmaraghy CA. Effects of nasal continuous positive airway pressure and cannula use in the neonatal intensive care unit setting. Arch Otolaryngol Head Neck Surg 2010; 136: 287-291.